The Latest Breaking News from FDA

Blue-chip dividend stocks are of well-established companies offering steady income and financial stability. They are ideal for securing a resilient retirement portfolio, combining consistent dividends with potential capital appreciation. Thus, quality blue-chip dividend stocks Johnson & Johnson (JNJ), Coca-Cola (KO), and McDonald’s (MCD) could be ideal portfolio additions for retirement…

The FDA, which approved the protocols for the studies it now questions, is asking for an additional Phase 3 clinical trial, which would take years and millions of dollars.

FDA declines approval for MDMA as PTSD treatment, citing safety and efficacy concerns. Further trials needed.

Federal health officials have declined to approve the psychedelic drug MDMA as a therapy for PTSD

From infusion pumps to nebulizers, home medical equipment comes with potential problems for users.

FDA approves Jemperli for endometrial cancer, revolutionizing treatment options with immunotherapy. Keytruda and Imfinzi expand personalized therapies.

President Trump's consideration of revoking access to the abortion pill mifepristone sparks debate on reproductive rights and access to abortion in the US.

Lawsuit filed against Abbott Nutrition over tainted infant formula linked to baby's death, raising awareness about powdered formula risks.

The parents of Kentucky baby who died last fall after drinking bacteria-tainted infant formula are the latest to sue manufacturer Abbott Nutrition